Dr Midgley is currently an Associate Professor in the College of Life Sciences. He obtained his BSc in Biomedical Sciences at Cardiff University in 2009 (Wales, UK), before completing his MSc in Tissue Engineering and Regeneration at Cardiff University in 2010 (full scholarship). He then embarked on a Research Into Ageing/AgeUK studentship-funded PhD at the Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University (October 2010 – October 2013). After obtaining his PhD he continued as a Postdoctoral Research Assistant at the Wales Kidney Research Unit, Cardiff University (funded by the UK MRC, 2013.10 - 2018.01). In March 2018, Dr Midgley joined Nankai University as a Postdoctoral Research Associate and National Natural Science Foundation of China (NSFC)-funded Research Fellow. He was appointed as a foreign faculty member and Associate Professor in June 2020, before being awarded NSFC International Excellent Young Scientist, Nankai University Baiqing Scholar, and appointed Fellow of the UK HEA (FHEA). Dr Midgley's research group mainly focuses on cellular and molecular mechanisms of organ fibrosis (kidney, liver, cardiovascular) and the development of functionalised nanomedicines for targeted anti-fibrotic gene and peptide therapy with the intent to prevent and potentially reverse chronic fibrotic diseases. His group's research directions include: 1. Treatment of organ fibrosis using hydrogels, nanomedicines, and associated composite materials (kidney, liver, heart); 2. Wound healing biomaterials (skin regeneration, anti-scarring therapies); 3. Molecular mechanisms of chronic diseases (Cell differentiation, matrix biology, and signaling pathways); 4. Gene and protein/peptide engineering for therapeutic development, enhanced nanomaterial targeting and efficacy； 5. Age-related effects on tissue regeneration (scarring vs. resolution), and biomarker discovery; 6. Organoids and organoid-inspired therapies, organoid-on-chip, 3D bioprinting. As of 2025, he has published >80 SCI publications (>30 as first/corresponding author); has applied for 4 invention patents in the fields of biomaterials and nanomaterials; 1 of which has been authorised. He holds two editorial board member positions, and serves as a regular reviewer for top SCI journals, including Bioactive Materials, Biomaterials, Nature Communications, Kidney International, ACS Nano, etc.